metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
R/R cHL - second line or more (L2) refractory classic Hodgkin lymphoma (R/R cHL) R/R cHL - second line or more (L2)
versus brentuximab vedotin
	pembrolizumab alone vs. brentuximab vedotin	1	none	inconclusive results for: DOR; AE leading to death (grade 5); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); Abdominal pain TRAE (grade 3-4); Acute kidney injury TRAE (grade 3-4); Anaemia TRAE (grade 3-4); Colitis TRAE (grade 3-4); Constipation TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Eczema TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Leucopenia TRAE (grade 3-4); Myocarditis TRAE (grade 3-4); Nausea TRAE (grade 3-4); Nephritis TRAE (grade 3-4); Paraesthesia TRAE (grade 3-4); Pneumonia TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Pyrexia TRAE (grade 3-4); Rash TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Urticaria TRAE (grade 3-4); Vomiting TRAE (grade 3-4)	statistically conclusive 35 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 68 % increase in objective responses (ORR) but the degree if certainty is unassessable suggested 73 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable	-

R/R cHL - second line or more (L2) refractory classic Hodgkin lymphoma (R/R cHL) R/R cHL - second line or more (L2)

versus brentuximab vedotin